Digital molecule designer Insilico Medicine has launched a preclinical research program focused on finding new treatments for brain cancer, and has brought on the former global program head of GlaxoSmithKline's computer-aided drug discovery unit to help run it. George Okafo will join Insilico as an entrepreneur-in-residence, as the company looks to wield its artificial intelligence networks and generative engines to uncover novel targets and molecules for glioblastoma multiforme, and potentially spin out the findings into a new business. "Brain cancers are the worst diseases anyone can ever get and the most rare cancers are often overlooked because the efforts are expensive, the market is small, and the probability of failure is high," Insilico co-founder and CEO Alex Zhavoronkov said in a statement. "We will try to change this with our AI-powered drug discovery pipeline." "We needed to have a seasoned big pharma veteran to drive this process to the point where it can be quickly developed and externalized," Zhavoronkov added, saying the company plans to use its AI to generate and evaluate several leads over the coming months, before hopefully setting the whole project off on its own by the end of August.